Medigene's Licensee enters promotion agreement to expand Veregen® product sales in the United States
Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "We are excited that Fougera has joined forces with Women's Choice Pharmaceuticals to expand Veregen®'s US business into the field of obstetrics, gynecology and urology. Fougera is now in a position to promote Veregen® to all appropriate physicians for the treatment of external genital warts. We believe this is an important agreement that will help to create broader brand recognition for Veregen® in the US."
In addition to the US, Veregen® is also available in Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries.
About Veregen®: Veregen® (sinecatechins) is a topical ointment for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. The product contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Sinecatechins 10% & 15% Ointment (Veregen®) have been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its 2010 Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes sinecatechins 15% Ointment (Veregen®) as an option for treating external genital warts.
About Women's Choice Pharmaceuticals LLC: Women's Choice Pharmaceuticals is a privately held specialty pharmaceutical company located in Gilbert, Arizona (USA). WCP is focused on acquiring, developing and licensing innovative prescription products in the women's health space. The company provides technology based prescription products to healthcare providers in the United States, with their current product portfolio consisting of patent protected products.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.com.